We report a case of myelodysplastic syndrome (MDS) occurring during the course of multiple myeloma (MM) treated by alkylating agents. Karyotype showed unbalanced t(5;17), resulting in 17p deletion. Dysgranulopoïesis typical of the '17p − syndrome' and p53 mutation and overexpression were present. A combination of FISH and immunophenotype analysis (FICTION, analysis) showed that 17p deletion was restricted to myeloid cells, and that p53 overexpression was also restricted to myeloid cells. These findings strongly argue against a common clonal origin of MM and MDS, and support the hypothesis that MM and MDS were clonally unrelated, and that MDS was indeed secondary to treatment with alkylating agents.
Introduction
17p deletion, resulting mainly from unbalanced translocation between 17p and another chromosome or less often from monosomy 17 or i(17q), is seen in 3-4% of myelodysplastic syndromes (MDS). This cytogenetic abnormality, which results in loss of one p53 allele (situated in 17p13), is generally associated with mutation of the non-deleted p53 allele and with a typical form of dysgranulopoiesis combining pseudo-PelgerHuët anomaly and small vacuoles in neutrophils. 1, 2 Multiple myeloma (MM) is complicated in 4-10% of cases by MDS, generally terminating in acute myeloid leukemia (AML). 3 It is generally believed that MDS occurring during the course of MM is clonally unrelated to the myeloma clone, and results from prolonged administration of alkylating agents. This is supported in particular by the fact that MDS very rarely occurs during the course of untreated MM. 4, 5 On the other hand, a few case reports where MDS shortly preceded MM, where both disorders were diagnosed simultaneously or where MDS occurred during the course of untreated MM, have led to the hypothesis that MM and MDS could originate from the same abnormal clone, at least in some cases. 3, 6 We report here a case of MDS with 17p deletion and p53 mutation occurring during the course of MM, where we found that 17p deletion and p53 mutation were restricted to myeloid cells, strongly suggesting that the MDS and MM clones were unrelated. 50 years. He was treated with continuous melphalan (for 6 months), then intermittent cyclophosphamide (for 2 years) followed by doxorubicin, CCNU (for 13 months), then cyclophosphamide, vincristine, procarbazine (for 5 months). Treatment was stopped in 1982 but restarted in 1986, with intermittent cyclophosphamide (for 16 months) followed by monthly courses of vincristine, cyclophosphamide, procarbazine, prednisone (29 courses).
Case report

Diagnosis of
In December 1995, anemia worsened and blood myelocytes and erythroblasts were seen. In June 1996, the serum monoclonal component increased to 25 g/l. The bone marrow aspirate showed 40% plasma cells of abnormal appearance. Conspicious dyserythropoiesis and dysgranulopoiesis were seen. The latter included typical pseudo-Pelger-Huët hypolobulation and the presence of small vacuoles in neutrophils. An excess of marrow blasts (6.5%) was present. A diagnosis of refractory anemia with excess of blasts supervening on MM was made. Cytogenetic analysis made after short-term (24 h) unstimulated culture showed 45, XY, −5, r(7), der(17) t(5;17) (p11, p12), +mar in 10 of the 13 mitoses examined.
Methods
Fluorescence in situ hybridization (FISH)
Whole chromosome painting (WCP) was made on metaphase spreads with cyanine-3 (Cy-3)-labeled WCP chromosome 17 probe and with fluorescein isothiocyanate (FITC)-labeled WCP chromosome 5 probe (Biovation, Aberdeen, UK) according to the manufacturer's instructions.
FISH analysis was performed on metaphase slides with a yeast artificial chromosome, YAC 914C7, obtained from the (7), a specific probe for p53 (Vysis, Woodcreek, IL, USA) and a chromosome 17 centromeric probe (D17Z1) (Vysis). Hybridization was performed as previously described 8 for the YAC probe and according to the manufacturer's instructions for p53 and D17Z1 probes.
A combination of FISH analysis with YAC 914C7 and immunophenotyping of marrow cells with monoclonal antibodies (MoAbs) specific for different cell lineages (Fluorescence Immunophenotyping and interphase Cytogenetics as a Tool for Investigation of Neoplasms or FICTION), was performed as previously described. 9 The MoAbs used were directed towards CD15 and kappa and lambda light chains (Dakopatts, Glostrup, Denmark).
Fluorescence signals were visualized on a Zeiss Axioskop epifluorescence microscope (Zeiss, Oberkochen, Germany) equipped with a double or triple bandpass filter. Fluorescence images were captured using the Quips Smart Capture FISH Imaging Software (Vysis).
Analysis of p53 mutation and expression
Detection of p53 mutation was made by single-stranded conformation polymorphism (SSCP) analysis and direct sequencing, as previously reported. 10 Analysis of p53 expression in marrow cells was made by immunocytochemical analysis of p53 using DO7 monoclonal antibody (Dakopatts), as previously published.
11 In our experience, detectable p53 expression in MDS and AML by this method is synonymous with the presence of a p53 missense mutation.
Results
WCP analysis confirmed the unbalanced translocation between chromosome 17 and chromosome 5, resulting in a 17p deletion. A small marker, containing chromosome 5 material, was also found (Figure 1a) .
FISH analysis showed only one signal for YAC 914C7 and p53 probes in metaphases (Figure 1b and e) .
FICTION analysis showed one signal for YAC914C7 in myeloid cells but two signals in B lymphocytes and plasma cells (Figure 1c and d) .
SSCP and direct sequencing showed the presence of a missense mutation of the p53 gene, involving codon 259 in exon 7 (GAC → TAC; Asp → Tyr) (not shown). Immunocytochemical analysis of p53 showed p53 overexpression in myeloid cells, but not in lymphocytes or plasma cells (Figure 1f) .
Discussion
In the present case report, typical features of therapy-related MDS were present: a history of prolonged administration of alkylating agents, complex cytogenetic abnormalities involving chromosomes 5, 7 and 17, the latter resulting in 17p deletion. Typical features of MDS with 17p deletion, 1 including an excess of marrow blasts, dysgranulopoïesis with pseudo-Pelger-Huët hypolobulation and small vacuoles in neutrophils and p53 mutation, were present. In our experience, about 30% of MDS and AML with 17p deletion are therapy related. 1 The fact that 17p deletion, resulting from t(5;17) translocation, and p53 overexpression resulting from p53 point mutation were present in granulocytes but not in plasma cells further supports the hypothesis that this patient had therapyrelated MDS, which arose at the level of myeloid progenitors and was not a clonal evolution of myeloma. The hypothesis that MDS and AML occurring during the course of MM constitute a clonal evolution of MM, at least in some cases, is based on two main findings: the description of AML occurring simultaneously with MM or during the course of untreated MM 3, 6 and rare case reports showing that the leukemic cells contained cytoplasmic immunoglobulins with the same heavy and light chains as the serum M proteins. 12 In two of the latter observations, however, it was shown that leukemic cells engulfed the M protein from the serum, but did not produce it. In addition, critical analysis of reported cases of AML and MDS occurring in association with untreated MM showed that their very low number probably reflected a coincidental or chance association between the two disorders. 6 Malignant transformation, in MM, may involve a pluripotent cell, as shown by the possible expression on MM cells of early B, T or even myelomonocytic markers. 13 However, no clear evidence that abnormal clones leading to MM can give rise to MDS or AML exist. Rather, AML and MDS occurring during the course of MM appear to be secondary to the antineoplastic agents used in the treatment of this disorder.
